vs

Side-by-side financial comparison of DNA X, Inc. (SONM) and Wave Life Sciences Ltd. (WVE). Click either name above to swap in a different company.

DNA X, Inc. is the larger business by last-quarter revenue ($16.2M vs $8.7M, roughly 1.9× Wave Life Sciences Ltd.). DNA X, Inc. runs the higher net margin — -29.3% vs -580.2%, a 550.9% gap on every dollar of revenue. On growth, DNA X, Inc. posted the faster year-over-year revenue change (7.9% vs -55.8%). Over the past eight quarters, DNA X, Inc.'s revenue compounded faster (9.9% CAGR vs -18.0%).

BIT Life Sciences is a for profit meetings, incentives, conferencing, exhibitions (MICE) company based in Dalian, China, that specializes in arranging multiple scientific congresses that have been described as "predatory". The company is part of a wave of organizations that have appeared in China in the past several years noted for arranging congresses with little academic merit and with the primary aim of generating revenue rather than scientific knowledge sharing. Papers submitted are usual...

SONM vs WVE — Head-to-Head

Bigger by revenue
SONM
SONM
1.9× larger
SONM
$16.2M
$8.7M
WVE
Growing faster (revenue YoY)
SONM
SONM
+63.8% gap
SONM
7.9%
-55.8%
WVE
Higher net margin
SONM
SONM
550.9% more per $
SONM
-29.3%
-580.2%
WVE
Faster 2-yr revenue CAGR
SONM
SONM
Annualised
SONM
9.9%
-18.0%
WVE

Income Statement — Q3 FY2025 vs Q2 FY2025

Metric
SONM
SONM
WVE
WVE
Revenue
$16.2M
$8.7M
Net Profit
$-4.8M
$-50.5M
Gross Margin
11.2%
Operating Margin
-24.5%
-606.5%
Net Margin
-29.3%
-580.2%
Revenue YoY
7.9%
-55.8%
Net Profit YoY
-89.2%
-53.3%
EPS (diluted)
$-4.83
$-0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SONM
SONM
WVE
WVE
Q3 25
$16.2M
Q2 25
$11.2M
$8.7M
Q1 25
$16.7M
$9.2M
Q4 24
$15.3M
Q3 24
$15.0M
Q2 24
$11.5M
$19.7M
Q1 24
$9.1M
$12.5M
Q4 23
$13.4M
$29.1M
Net Profit
SONM
SONM
WVE
WVE
Q3 25
$-4.8M
Q2 25
$-7.5M
$-50.5M
Q1 25
$458.0K
$-46.9M
Q4 24
$-21.6M
Q3 24
$-2.5M
Q2 24
$-6.6M
$-32.9M
Q1 24
$-2.9M
$-31.6M
Q4 23
$-1.4M
$-16.3M
Gross Margin
SONM
SONM
WVE
WVE
Q3 25
11.2%
Q2 25
7.6%
Q1 25
50.0%
Q4 24
-1.2%
Q3 24
28.2%
Q2 24
25.8%
Q1 24
31.8%
Q4 23
38.1%
Operating Margin
SONM
SONM
WVE
WVE
Q3 25
-24.5%
Q2 25
-60.2%
-606.5%
Q1 25
3.9%
-542.8%
Q4 24
55.3%
Q3 24
-15.8%
Q2 24
-56.2%
-177.7%
Q1 24
-29.5%
-274.8%
Q4 23
-9.3%
-64.3%
Net Margin
SONM
SONM
WVE
WVE
Q3 25
-29.3%
Q2 25
-66.8%
-580.2%
Q1 25
2.7%
-510.9%
Q4 24
-141.6%
Q3 24
-16.7%
Q2 24
-57.5%
-167.2%
Q1 24
-31.9%
-251.7%
Q4 23
-10.1%
-55.9%
EPS (diluted)
SONM
SONM
WVE
WVE
Q3 25
$-4.83
Q2 25
$-0.79
$-0.31
Q1 25
$0.08
$-0.29
Q4 24
$-116.99
Q3 24
$-9.32
Q2 24
$-1.41
$-0.25
Q1 24
$-0.65
$-0.24
Q4 23
$-0.26
$-0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SONM
SONM
WVE
WVE
Cash + ST InvestmentsLiquidity on hand
$2.1M
$208.5M
Total DebtLower is stronger
$5.1M
Stockholders' EquityBook value
$-701.0K
$139.3M
Total Assets
$40.2M
$252.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SONM
SONM
WVE
WVE
Q3 25
$2.1M
Q2 25
$2.0M
$208.5M
Q1 25
$2.1M
$243.1M
Q4 24
$5.3M
Q3 24
$9.1M
Q2 24
$9.6M
$154.0M
Q1 24
$9.3M
$180.9M
Q4 23
$9.4M
$200.4M
Total Debt
SONM
SONM
WVE
WVE
Q3 25
$5.1M
Q2 25
$2.9M
Q1 25
$2.8M
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
Stockholders' Equity
SONM
SONM
WVE
WVE
Q3 25
$-701.0K
Q2 25
$-1.3M
$139.3M
Q1 25
$-1.1M
$171.8M
Q4 24
$-5.7M
Q3 24
$15.3M
Q2 24
$17.5M
$-3.5M
Q1 24
$19.8M
$25.4M
Q4 23
$22.4M
$39.6M
Total Assets
SONM
SONM
WVE
WVE
Q3 25
$40.2M
Q2 25
$36.1M
$252.4M
Q1 25
$36.0M
$288.3M
Q4 24
$39.7M
Q3 24
$49.1M
Q2 24
$45.9M
$208.8M
Q1 24
$42.4M
$235.3M
Q4 23
$56.0M
$274.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SONM
SONM
WVE
WVE
Operating Cash FlowLast quarter
$-7.0M
$-46.0M
Free Cash FlowOCF − Capex
$-46.3M
FCF MarginFCF / Revenue
-532.5%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-170.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SONM
SONM
WVE
WVE
Q3 25
$-7.0M
Q2 25
$-4.9M
$-46.0M
Q1 25
$-9.6M
$-63.0M
Q4 24
$-4.5M
Q3 24
$-417.0K
Q2 24
$-3.4M
$-27.5M
Q1 24
$-168.0K
$-33.4M
Q4 23
$-351.0K
$-33.2M
Free Cash Flow
SONM
SONM
WVE
WVE
Q3 25
Q2 25
$-46.3M
Q1 25
$-63.2M
Q4 24
$-4.5M
Q3 24
$-554.0K
Q2 24
$-3.4M
$-27.5M
Q1 24
$-198.0K
$-33.8M
Q4 23
$-33.6M
FCF Margin
SONM
SONM
WVE
WVE
Q3 25
Q2 25
-532.5%
Q1 25
-688.9%
Q4 24
-29.6%
Q3 24
-3.7%
Q2 24
-29.8%
-139.8%
Q1 24
-2.2%
-270.0%
Q4 23
-115.6%
Capex Intensity
SONM
SONM
WVE
WVE
Q3 25
Q2 25
3.5%
Q1 25
1.8%
Q4 24
0.1%
Q3 24
0.9%
Q2 24
0.3%
0.3%
Q1 24
0.3%
3.3%
Q4 23
1.2%
Cash Conversion
SONM
SONM
WVE
WVE
Q3 25
Q2 25
Q1 25
-20.97×
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons